Navigation Links
Upsher-Smith Announces Commercial Availability Of Morphine Sulfate ER Capsules
Date:8/29/2013

MAPLE GROVE, Minn., Aug. 29, 2013 /PRNewswire/ -- Upsher-Smith Laboratories, Inc., today announced its Morphine Sulfate Extended-Release Capsules, CII will be commercially available on September 4, 2013.

(Logo:  http://photos.prnewswire.com/prnh/20130520/NY17281LOGO )

Historically, there have been a limited number of morphine sulfate generics available.  Upsher-Smith used its extensive formulation experience to overcome the challenges presented.

Upsher-Smith's family of Morphine Sulfate Extended-Release Capsules, CII includes seven dosage strengths: 10 mg, 20 mg, 30 mg, 50 mg, 60 mg, 80 mg, and 100 mg.  This will be the first generic entrant for the 10-mg extended-release capsule dosage strength.1 Upsher-Smith's generic drug segment is dedicated to providing high-quality pharmaceutical products that are affordable and accessible to patients.

About Upsher-Smith
Upsher-Smith is an independent specialty pharmaceutical company dedicated to its mission of Advancing Pharmacotherapy to Improve Life™. Upsher-Smith currently leverages its core strength in formulation development to drive both branded and generic therapeutic solutions to address patients' needs ranging in scope from women's health to cardiology. The Company has a particular focus on developing therapies for people living with challenging central nervous system conditions like epilepsy, and has an emerging neurology pipeline with three products in clinical development.  For more information, visit www.upsher-smith.com.

Please see Full Prescribing Information, including Boxed Warning, at http://www.upsher-smith.com/wp-content/uploads/MorphineSulfate_MI.pdf.

References
1. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. http://www.accessdata.fda.gov/scripts/cder/ob/docs/tempai.cfm.  Accessed May 9, 2013.


'/>"/>
SOURCE Upsher-Smith Laboratories, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Upsher-Smith Teams Up With Epilepsy Foundation Of Minnesota For 2013 Stroll For Epilepsy
2. Upsher-Smith Announces Patient Enrollment In Open-label Safety Study Of USL261 (Intranasal Midazolam) For Rescue Treatment Of Seizure Clusters In Epilepsy
3. Upsher-Smith Is Honored With Prestigious Industry Award For Leadership And Innovation
4. Upsher-Smith Successfully Completes Phase III Study Of USL255 (Extended-Release Topiramate) For Adjunctive Treatment Of Epilepsy In Patients With Refractory Partial-Onset Seizures
5. Upsher-Smith Introduces Newly Redesigned Corporate Website
6. Upsher-Smith Presents Data Supporting Favorable Tolerability And Consistent Pharmacokinetic Profile Of Once-Daily USL255 (Extended-Release Topiramate)
7. Emerging Data From Upsher-Smiths CNS Portfolio Highlighted At 2013 American Academy Of Neurology Meeting
8. Doug Zitnak of Upsher-Smith Laboratories Named Small Brand Manufacturer Representative of the Year By Cardinal Health
9. Tina Fehr, Senior Product Manager For AmLactin, Upsher-Smith Laboratories Named PM360 Trailblazer Winner For Womens Health Brand Manager
10. Upsher-Smith Teams Up With Epilepsy Foundation of Minnesota for 2012 Stroll for Epilepsy
11. Upsher-Smith Is Honored with Prestigious Industry Award for Excellence and Innovation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... DUBLIN , Mar. 29, 2017 ... "Intraoperative Neuromonitoring (IONM) Market Size & Forecast By Type (Insource ... - 2025" report to their offering. ... The global Intraoperative ... by 2025. The intraoperative neuromonitoring market is anticipated to witness ...
(Date:3/29/2017)... March 29, 2017 Global intravenous (IV) iron and ... by 2021, growing at a CAGR of 5%. ... a doctor to treat anemia or other iron deficiencies. Oral ... the body. However, in some cases, oral administrations are not ... intravenous (IV) iron therapy comes into the picture. ...
(Date:3/29/2017)... 29, 2017 Today, CVS Health officials (NYSE: ... , Department of Public Health Director Gerd Clabaugh ... in announcing the availability of the opioid overdose-reversal medicine ... Iowa.  CVS Health has established a standing order with physicians ... to expand access to the medication in the state.   ...
Breaking Medicine Technology:
(Date:3/29/2017)... , ... March 29, 2017 , ... Curio Wellness ... to announce the finalization of the company’s executive management team with prominent executives from ... operations is Curio Wellness’ Chief Operating Officer, Ted Dumbauld , who has more ...
(Date:3/29/2017)... ... March 29, 2017 , ... HealthCareMandA.com will host an ... 20, 2017, at 1:00 PM ET. A recording of the webinar will also be ... Series. , Home health and hospice companies are still popular targets for healthcare investors. ...
(Date:3/29/2017)... ... ... Immunotherapy has emerged as one of the most promising options for the ... next revolution in our fight against this complex disease. One of the most effective ... such as PD-1 and PD-L1 inhibitors. , While a few single analyte immunohistochemistry tests ...
(Date:3/29/2017)... ... March 29, 2017 , ... ... of Pittsburgh now have easier access to the robotic-assisted total-hip and partial-knee ... Network (AHN). Orthopaedic surgeons at Forbes Hospital and Jefferson Hospital recently started ...
(Date:3/29/2017)... ... March 29, 2017 , ... The Wharton School of the ... Taffet Moelis, W’81, have made a $10 million gift to establish the Ken ... will provide a pathway to a Wharton MBA for highly-qualified Penn undergraduates whose academic ...
Breaking Medicine News(10 mins):